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Abstract
As an important post-translation modifying process, glycosylation significantly affects the structure and function of immunoglobulin G
(IgG) molecules and is essential in many steps of the inflammatory cascade. Studies have demonstrated the potential of using
glycosylation features of IgG as a component of predictive biomarkers for chronological age in several European populations,
whereas no study has been reported in Chinese. Herein, we report various patterns of changes in IgG glycosylation associated with
age by analyzing IgG glycosylation in 701 community-based Han Chinese (244 males, 457 females; 23–68 years old). Eleven IgG
glycans, including FA2B, A2G1, FA2[6]G1, FA2[3]G1, FA2[6]BG1, FA2[3]BG1, A2G2, A2BG2, FA2G2, FA2G2S1, and FA2G2S2,
change considerably with age and specific combinations of these glycan features can explain 23.3% to 45.4% of the variance in
chronological age in this population. This indicates that these combinations of glycan features provide more predictive information
than other single markers of biological age such as telomere length. In addition, the clinical traits such as fasting plasma glucose and
aspartate aminotransferase associated with biological age are strongly correlated with the combined glycan features. We conclude
that IgG glycosylation appears to correlate with both chronological and biological ages, and thus its possible role in the aging process
merits further study.
Abbreviations: ADCC = antibody-dependent cellular cytotoxicity, ALT = alanine aminotransferase, AST = aspartate
aminotransferase, BMI = body mass index, Cr = creatinine, DBP = diastolic blood pressure, Fc = crystallizable fragment, FPG =
fasting plasma glucose, GlcNAc = N-acetylglucosamine, GP = glycan peak, HDL = high-density lipoprotein, Ig = immunoglobulin,
IgG= immunoglobulin G, LDL= low-density lipoprotein, MCV=mean corpuscular volume, SBP= systolic blood pressure, TC= total
cholesterol, UA = uric acid, UPLC = ultra-performance liquid chromatography, WBC = white blood cell count.
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1. Introduction
Aging is a progressive process of loss of physiological integrity,
including molecular, cellular, and organ impairment, and finally
increased chronic inflammation and vulnerability to disease and
death.[1] Decades of research demonstrate that more active and
healthier lifestyle such as continued physical activity and smoking
cessation may delay the aging process.[2,3] With these observa-
tions, research in screeningmolecular markers of age to predict or
monitor the age-associated physiological decline and disease has
experienced an unprecedented advance over recent years.[1]
Perturbed proteostasis such as secretion of unfolded, misfolded,
or aggregated proteins and incorrect degradation of proteins
has been proved to be associated with aging and age-related
pathologies.[4–7] The polypeptide sequence of a protein will not
changewith age because it is definedby the sequence of nucleotides
in the relevant genes. However, as an intricate post-translation
modifying process, over half of protein and almost all membrane
and secreted proteins are glycosylated during the formation
process.[8] Structural changes of the attached glycans are of great
physiological significance and many pathological conditions are
associated with various types of glycan changes.[9,10] Diverse
plasma glycans were shown to be closely related to aging over 25
years ago [11] and the associations have also been replicated in
recent studies in European [12–14] and Chinese population.[15]
Immunoglobulins (Igs) are a group of proteins with antibody
activity (immunoglobulin G [IgG], IgM, IgA, IgE, and IgD)
accounting for approximately 20% of plasma proteins, and
among them IgG is the most abundant (>80%).[16] IgG is
considered as a perfect model glycoprotein because of its well-
defined glycan structures and functions.[10] It consists of 2
identical light chains and heavy chains, which are joined by
covalent bonds to form a “Y-shaped” structure.[17] The 2
domains of IgG that are responsible for their in vivo properties
are the antigen-binding fragment and the crystallizable fragment
(Fc).[18] A single, N-linked glycosylation site exists at the amino
acid 297 in the heavy chain of all IgG subclasses.[19] The fine
changes in attached glycan composition can dramatically change
the conformation of the Fc domain with significant consequences
for effector functions of IgG.[10] The addition of terminal sialic
acid to this glycan reduces Fcg receptors (FcgRs) binding and
converts IgG antibodies from pro-inflammatory to anti-inflam-
matory mediators through the lectin receptor SIGN-R1 or DC-
SIGN (dendritic cell-specific intercellular adhesion molecule-3-
grabbing nonintegrin), which upregulates surface expression of
the inhibitory Fc receptor, FcgRIIb, on inflammatory cells,
thereby attenuating autoantibody-initiated inflammation.[20]
Another important role that glycosylation plays in IgG is
modulation of antibody-dependent cellular cytotoxicity (ADCC):
the addition of fucose residue in the core of the glycan (core
fucose) modifies the conformation of the Fc domain in a way to
significantly reduce its affinity for FcgRIIIa; therefore, core-
fucosylated IgGs are less efficient in activating ADCC.[21] Most of
IgGs (>95%) are core fucosylated, which can prevent them from
wrong elicitation of ADCC.[22] Malfunction of IgG glycosylation
appears to be associated with the incidence and development of
many inflammatory and autoimmune diseases, such as rheuma-
toid arthritis,[23,24] systemic lupus erythematosus,[25,26] psoriatic
arthritis,[27] Alzheimer disease, and progressive mild cognitive
impairment.[28] Meanwhile, the level of galactosylation in female
Japanese was suggested to decrease with aging.[29]
Considering the crucial role of IgG glycans in inflammatory
cascade, and because aging is an inflammation-related progress,
researchers have been investigating the glycosylation changes of
IgG or total plasma proteins with age in several European
populations.[30–33] Their observed results from the total plasma
glycome cannot eliminate the effects from various concentrations
of other plasma proteins. In this study, we focused on the
glycosylation of IgG and analyzed 701 individuals from a
community-based Han Chinese population to show the changes
in IgG glycosylation with age.
2. Materials and methods
2.1. Study design and participant recruitment
This study has been approved by the Ethics Committee of the
Capital Medical University, Beijing, China. The ethics approval
was given in compliance with the Declaration of Helsinki (World
Medical Association, 2000). Each participant included in this
study signed informed consent.
An observational cross-sectional study was conducted during
2012, and a total of 701 (23–68 years old) participants of Chinese
Han ancestry were recruited from a community-based survey in
Beijing. The volunteer participants who met the following
inclusion criteria were recruited: no physical and mental
abnormalities history registered in their medical records and
no medication history during the past 2 weeks. Individuals
diagnosed with serious diseases involving the cardiovascular and
cerebrovascular system, respiratory system, genitourinary sys-
tem, digestive system, and hematic system were excluded.
2.2. Collection of clinical traits
Each participant was required to complete a thorough health
examination, which consisted of >30 test items, including
anthropometric measurements, and physical and chemical prop-
erties of blood. For the anthropometric traits, physical examina-
tions and interviews were carried out by trained nurses and
physicians. For the blood traits (hematology and biochemical
traits), fasting blood sampleswere collected in themorning after an
overnight fasting by venipuncture for standard blood chemistry
and hematology assays (Hitachi Automatic Analyzer, Model-
7600, Tokyo, Japan), which were conducted at the Medical
LaboratoryofXuanwuHospital, Beijing.After excluding resultsof
qualitative tests and results with missing value, the following 38
clinical traits were assessed in the current study:
(a) Results of anthropometric tests: Height (in centimeters) and
weight (in kilograms) were measured after participants
removed their shoes and hats, any heavy objects from their
pockets, and any heavy or bulky outer sweaters or jackets.
Body mass index (BMI, kg/m2) was calculated as weight in
kilograms divided by height in meters squared. Waist
circumference (cm) measurement was taken by wrapping a
measuring tape around the natural waist at the navel and hip
circumference (cm) measurement was taken over the fullest
part of the hips horizontally. Systolic blood pressure (SBP,
mmHg) and diastolic blood pressure (DBP, mmHg) were
measured twice on the right arm by trained nurses using a
standard mercury sphygmomanometer with the participants
resting at least 5min in a sitting position.
(b) Results of biochemical assays: These included fasting plasma
glucose (FPG, mmol/L), total cholesterol (TC, mmol/L),
triglyceride (mmol/L), low-density lipoprotein (LDL, mmol/
L), high-density lipoprotein (HDL, mmol/L), alanine amino-
transferase (ALT, IU/L), aspartate aminotransferase (AST,
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IU/L), creatinine (Cr, mmol/L), uric acid (UA, mmol/L), and
urea (mmol/L).
(c) Results of hematology assays: These comprised white blood
cell count (WBC, 109/L), red blood cell count (1012/L),
hemoglobin concentration (g/L), hematocrit (%), blood
platelet count (109/L), mean corpuscular volume (MCV,
fL), mean corpuscular hemoglobin (pg), mean corpuscular
hemoglobin concentration (g/L), neutrophil count (109/L),
lymphocyte count (109/L), eosinophil count (109/L), basophil
count (109/L), monocyte (109/L), eosinophil ratio (%),
basophil ratio (%), mean platelet volume (fL), platelet
hematocrit (%), neutrophil percentage, lymphocyte percent-
age, monocyte percentage, red cell distribution width (%),
and platelet distribution width (%).
2.3. IgG Glycosylation Analysis
2.3.1. Plasma sample preparation. Fasting blood samples were
collected from patients in the morning using ethylenediaminete-
traacetic acid Vacutainer tube by the trained nurses. The tubes
were placed in a cool box with ice blocks and brought to lab
within 6 hours. Then the plasma samples were separated after
centrifugation at 2000rpm for 15 minutes and immediately
stored at 80°C for glycosylation analysis.
2.3.2. Isolation of IgG from human plasma. The IgG was
isolated using protein G monolithic plates as described
previously.[34] Briefly, after washing and equilibrating protein
G monolithic plates, 90mL of plasma was diluted 10 with
binding buffer (1 phosphate-buffered saline, pH 7.4), applied to
the protein G plate, and instantly washed. IgGs were eluted with
1mL of 0.1M formic acid and immediately neutralized with 1M
ammonium bicarbonate.[34]
2.3.3. N-Glycan release and labeling. N-Glycan release and
labeling of IgG were performed as reported by Menni et al.[35]
Briefly, isolated IgG samples were dried and denatured with
addition of 20mL 2% sodium dodecyl sulfonate (w/v). After
incubation at 60°C for 10minutes, 10mL of 4% IGEPALCA-630
and 0.5mU of PNGase F in 10mL 5 phosphate-buffered saline
were added to the samples. The samples were then incubated
overnight at 37°C for N-glycan release. The released N-glycans
were labeled with 2-aminobenzamide, a fluorescent dye used to
make glycans visible by ultra-performance liquid chromatogra-
phy (UPLC), by multistage mixing with 2-aminobenzamide,
dimethylsulfoxide, glacial acetic acid, and 2-picoline borane.
Labeled glycans were cleaned and eluted using hydrophilic
interaction liquid chromatography–solid phase extraction, and
the combined elutes were either analyzed immediately by UPLC
or stored at 20°C until usage.
2.3.4. Analysis of IgG N-glycans. IgG N-glycans were
separated by hydrophilic interaction liquid chromatography on
a Waters ACQUITY UPLC instrument (Walters Corporation,
Milford, MA) into 24 glycan chromatographic peaks (GP1–24)
and quantified as relative contributions of individual peak to the
total IgG N-glycome. Structures of glycans in each peak were
determined by mass spectrometry and represented by alphanu-
meric characters (see Table 1, Supplemental Content, http://links.
lww.com/MD/B95, which illustrates the glycan structures in the
IgG glycome). In short, 2N-acetylglucosamines (GlcNAcs) and 3
mannose residues are combined to form the core sugar sequence
for each IgGN-glycan. Based on that core structure, F represents
a core fucose a-1 to -6 linked to the inner GlcNAcs; Ax, number
(x) of GlcNAc (antenna) linked to the inner trimannose residues;
Gx, number (x) of galactose on antenna-linked GlcNAc; Sx,
number (x) of sialic acid residue on galactose; Mx, number (x) of
mannose linked to core GlcNAcs; and B, bisecting GlcNAc linked
to core mannose.[34] The minor glycan peak (GP), GP3, was
excluded from all the calculations because in some samples it
coeluted with a contaminant that significantly affected its value,
and GP20 was also eliminated as its glycan structure has not been
determined.
2.4. Statistical analysis
2.4.1. Descriptive analysis of glycan structures. Among the
total 24 GPs, GP3 and GP20 were excluded from all of the
following statistical analyses due to the reason mentioned
previously. All analyses were performed with R programming
language[36] (R Core Team, 2013). All reported P values were
2-sided, and P<0.05 was considered statistically significant.
Normality distributions of all variables were tested by Shapiro–-
Wilk test (“fBasics” package) (see Tables 2 and 3, Supplemental
Content, http://links.lww.com/MD/B95, which illustrate the
normality tests of IgG N-glycans before and after log
transformation). A log transformation was performed on the
22 glycan variables to obtain normally distributed variables. For
most of the variables that were not normally distributed, median
together with interquartile range was used in descriptive statistics
(see Table 4, Supplemental Content, http://links.lww.com/MD/
B95, which illustrates the description of IgG N-glycans).
Correlation coefficient matrices of IgG N-glycan structures,
age, and clinical traits in both sexes were assessed independently
by Spearman rank correlation method (“psych” package). Sex
differences in IgG N-glycans and clinical traits were tested by
Mann–Whitney U tests or 2-sample t test according to the results
of normality tests of the data.
2.4.2. Prediction of chronological age from glycan struc-
tures. Based on the assumption of association between glycans
and age, and considering the significant difference of glycan
structures among sex, we decided to build 3 predictive models of
chronological age using the glycan structures with the pooled
(males and females), male, and female samples, respectively, that
is, 3 models: GlyAge-Pooled, GlyAge-Male, and GlyAge-Female
models. Glycan structures that were statistically related with
chronological age were used as potential independent variables
for the 3 predictive models. The best combination of glycan
structures in the final models was determined using all-subsets
regression (“leaps” package). Considering the loss of information
in nonparametric test, and because not all variables could be
successfully transformed to normality, the predictive models of
chronological age were built using binominal regression (“stats”
package) and permutation test approach (“lmPerm” package).
Binominal regression was first applied to estimate the model
coefficient, and the best model was determined for each sex
according to the Akaike information criterion. The maximal age
predictive model included linear and quadratic terms for each of
the age-related glycan structures. Finally, the best models based
on pooled, male, and female samples were determined separately
according to the Akaike information criterion (“aod” pack-
age)[37] and the values of adjusted R-squared and then named as
GlyAge-Pooled, GlyAge-Male, and GlyAge-Female models. The
GlyAge-Pooled, GlyAge-Male, and GlyAge-Female indexes that
integrated different GPs were obtained from each established
model.
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2.4.3. Association analysis of GlyAge-Pooled, GlyAge-Male,
and GlyAge-Female indexes with clinical traits. To identify the
clinical (anthropometric, hematological, and biochemical) traits
that might be accountable for the differences between predicted
age and chronological age, we performed association analysis
with the 38 clinical traits in pooled, male, and female samples
independently. In pooled samples, we defined 2 equations for
each trait:
Predicted age
e
ageþ sex
Predicted age
e
ageþ sexþ trait
Analysis of variance test (“stats” package) was performed on
those equations to identify the traits that can significantly
reduce the residual sum of squares of the equations. In male
and female samples, we determined the clinical traits that may
be responsible for the differences between predicted and
chronological ages in a similar way, just without the sex
variable.
2.4.4. Prediction of chronological age with glycan structures
and clinical traits. The predictive models of chronological age
that combined clinical traits and glycan structures were built in
the same way as GlyAge-Pooled, GlyAge-Male, and GlyAge-
Female models and named as GlyCliAge-Pooled, GlyCliAge-
Male, and GlyCliAge-Female accordingly. For the 3 combined
models, the clinical traits that were tested to be associated with
chronological age and the GPs involved in the previous 3 indexes
were included in the maximum model. Additionally, the
performances of the 3 combined models were tested on pooled,
male, and female samples.
3. Results
3.1. Description of clinical traits
In total, 38 clinical traits (6 anthropometric, 10 biochemical, and
22 hematology traits) of all participants were described and
compared in different sexes (Table 1).Most of the traits (30 out of
38) were significantly different between males and females (P<
0.05). In terms of anthropometric traits, the levels of BMI, SBP,
DBP, and waist circumference in males were significantly higher
than those in females. The same situation also occurred in levels
of 5 biochemical traits including FPG, triglyceride, ALT, AST,
and Cr, whereas higher level of HDL was found in females.
For hematology traits, the values of the inflammation-related
parameters (WBC, neutrophil count, lymphocyte count, eosino-
phil count, basophil count, monocyte, neutrophil percentage, and
monocyte percentage) were higher in males. To some extent, all
the aforementioned traits are well known to be correlated with
inflammatory cascade, inflammation-linked diseases, or aging
process.[1,38]
3.2. IgG N-glycan structures of participants
IgG N-glycan analysis was performed on 701 (244 males, 457
females) Chinese Han participants. Monogalactosylated glycan
(FA2[6]G1) had the highest concentrations in pooled and male
samples (median: 18.58% and 18.69%, respectively), whereas
the digalactosylated glycan (FA2G2) accounts for the largest
proportion of the glycan structures in females (median: 18.91%).
Among the total 22 GPs, the values of 10 GPs (FA1, A2, FA2,
M5, FA2B, A2G1, FA2[6]BG1, FA2[3]BG1, FA2BG2S1, and
FA2BG2S2) were significantly higher in males, whereas another 4
GPs (A2G2, FA2G2, FA2BG2, and FA2G2S1) were observed to
be of higher values in females (P<0.001), indicating the different
level of galactosylation and sialylation between sexes. Compared
with females, males had a higher proportion of nongalactosylated
(FA1, A2, FA2, M5, FA2B), monogalactosylated (A2G1, FA2[6]
BG1, FA2[3]BG1), and disialylated (FA2BG2S2) glycans (P<
0.001) (Table 2; see Table 1, Supplemental Content, http://links.
Table 1
Difference of clinical traits between males and females
∗
.
Parameters Pooled Male Female P value
Number, % 701 (100) 244 (34.8) 457 (65.2)
Age, y 48 (10) 48 (8) 47 (6) 0.050
Anthropometric traits
BMI, kg/m2 24.4 (4.1) 25.7 (4.0) 23.8 (3.7) 0.000†
SBP, mmHg 120 (16) 120 (20) 118 (16) 0.000†
DBP, mmHg 80 (16) 80 (10) 79 (10) 0.000†
WC, cm 79 (13) 85 (10) 76 (11) 0.000†
HC, cm 95 (7) 96 (5) 95 (9) 0.654
Heart rate, beats/min 76 (10) 76 (12) 76 (10) 0.340
Biochemical traits
FPG, mmol/L 5.21 (0.77) 5.45 (0.98) 5.08 (0.69) 0.000†
TC, mmol/L 5.07 (1.23) 5.05 (1.29) 5.09 (1.20) 0.878
TG, mmol/L 1.15 (0.95) 1.58 (1.45) 1.02 (0.75) 0.000†
LDL, mmol/L 2.77 (0.93) 2.86 (1.01) 2.72 (0.88) 0.148
HDL, mmol/L 1.6 (0.43) 1.43 (0.37) 1.70 (0.41) 0.000†
ALT, IU/L 17 (11) 22 (14) 15 (8) 0.000†
AST, IU/L 19 (7) 21 (8) 18 (5) 0.000†
Cr, mmol/L 54 (17) 69 (13) 50 (8) 0.000†
Urea, mmol/L 5.12 (1.64) 5.60 (1.67) 4.90 (1.50) 0.000†
UA, mmol/L 248 (112) 326 (85) 215 (72) 0.000†
Hematology traits
WBC, 109/L 5.99 (1.96) 6.43 (2.33) 5.73 (1.89) 0.000†
RBC, 1012/L 4.57 (0.55) 4.93 (0.42) 4.41 (0.41) 0.000†
Hb, g/L 138 (21) 154 (13) 132 (13) 0.000†
HCT, % 40.70 (5.10) 44.55 (3.18) 39.30 (3.30) 0.000†
PLT, 109/L 240 (70) 221 (60) 252 (72) 0.000†
MCV, fL 89.90 (5.20) 90.35 (5.28) 89.70 (5.20) 0.000†
MCH, pg 30.7 (1.9) 31.4 (1.5) 30.2 (2) 0.000†
MCHC, g/L 340 (12) 346 (10) 336 (11) 0.000†
NEUT, 109/L 3.42 (1.47) 3.56 (1.73) 3.35 (1.46) 0.000†
LYMPH, 109/L 1.97 (0.75) 2.195 (0.82) 1.91 (0.70) 0.000†
EOS, 109/L 0.10 (0.10) 0.14 (0.14) 0.09 (0.08) 0.000†
BASO, 109/L 0.02 (0.01) 0.03 (0.02) 0.02 (0.02) 0.000†
MONO, 109/L 0.35 (0.15) 0.41 (0.16) 0.32 (0.13) 0.000†
EOSR, % 1.70 (1.60) 2.20 (1.88) 1.60 (1.50) 0.000†
BASOR, % 0.4 (0.4) 0.4 (0.3) 0.4 (0.4) 0.318
RDW, % 12.7 (0.8) 12.6 (0.7) 12.7 (0.9) 0.000†
PDW, % 12.30 (2.40) 12.45 (2.70) 12.30 (2.30) 0.129
MPV, fL 10.80 (1.05) 10.80 (1.18) 10.80 (1.00) 0.558
PCT, % 0.26 (0.08) 0.24 (0.06) 0.27 (0.08) 0.000†
NEUT% 57.50 (10.85) 56.00 (9.93) 58.50 (11.55) 0.007†
LYMPH% 33.60 (10.15) 34.10 (10.05) 33.40 (9.90) 0.639
MONO% 5.70 (1.90) 6.30 (1.78) 5.60 (1.75) 0.000†
ALT= alanine aminotransferase, AST = aspartate aminotransferase, BASO = basophil count, BASOR
= basophil ratio, BMI = body mass index, Cr = creatinine, DBP = diastolic blood pressure, EOS =
eosinophil count, EOSR= eosinophil ratio, FPG= fasting plasma glucose, Hb= hemoglobin, HC= hip
circumference, HCT = hematocrit, HDL = high-density lipoprotein, LDL = low-density lipoprotein,
LYMPH = lymphocyte count, LYMPH% = lymphocyte percentage, MCH = mean corpuscular
hemoglobin, MCHC = mean corpuscular hemoglobin concentration, MCV = mean corpuscular
volume, MONO = monocyte, MONO% = monocyte percentage, MPV = mean platelet volume,
NEUT = neutrophil count, NEUT% = neutrophil percentage, PCT = platelet hematocrit, PDW =
platelet distribution width, PLT = blood platelet count, RBC = red blood cell count, RDW = red cell
distribution width, SBP = systolic blood pressure, TC = total cholesterol, TG = triglyceride, UA = uric
acid, WBC = white blood cell count, WC = waist circumference.
∗
Data are presented as median (interquartile range).
† P<0.05; difference between male and female is statistically significant.
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lww.com/MD/B95, which illustrates the glycan structures in
the IgG glycome), that is, the males had a lower level of
galactosylation and a higher level of disialylation.
3.3. Relationship between IgG glycosylation and
chronological age
Nineteen (GP1, 2, 4–15, 17–19, 21, and 23) out of 22 GPs in the
pooled samples were statistically significantly associated with
age. Among these 19 GPs, 11 GPs (GP2, 4, 6, 8, 10, 11, 13, 14,
18, 19, and 23) in males and 18 GPs (GP1, 2, 4–15, 17, 18, 21,
and 23) in females were found to be related with age. Meanwhile,
10GPs (GP2, 4, 6, 8, 10, 11, 13, 14, 18, and 23) that represent the
structures of A2, FA2, FA2B, FA2[6]G1, FA2[6]BG1, FA2[3]
BG1, A2BG2, FA2G2, FA2G2S1, and FA2G2S2, respectively,
were constantly correlated with age in all 3 groups (pooled, male,
and female samples) and the association was stronger in females
(0.203< jRj<0.576, P<0.001) than in males (0.135< jRj<
0.368, P<0.001).
The top glycan structure correlated with age is FA2B, a
nongalactosylated nonsialylated glycan, in both males (R=
0.368, P<0.001) and females (R=0.576, P<0.001). Non-
galactosylated (A2, FA2, and FA2B) and monogalactosylated
(FA2[6]BG1 and FA2[3]BG1) glycans steadily increased with
age, whereas digalactosylated glycans (A2BG2, FA2G2,
FA2G2S1, and FA2BG2S2) steadily decreased with age in both
males and females. The only exception was the monogalactosy-
lated glycan without bisecting GlcNAc (FA2[6]G1), which
decreased with age in males (R=0.135, P=0.04) but increased
in females (R=0.223, P<0.001) (Table 3). The relationship
between glycan levels and age was changed more dramatically in
females than in males.Most overlap of the fitted value in different
sexes was accorded between 50 and 60 years of age, which was
correlated with the time when most of the women had gradually
adapted to the menopause (Fig. 1; see Fig. Supplemental Content,
http://links.lww.com/MD/B95, which illustrates the relationship
between age and glycan structures).
Although the association between sialylation and age wasmore
complicated, the biantennary digalactosylated glycans with 1 or 2
Table 2
Descriptive statistics for GPs by sex
∗
.
GP Pooled, % Male, % Female, %
P value
(U statistic)
GP1 0.06 (0.05) 0.07 (0.05) 0.06 (0.04) 0.000†
GP2 0.34 (0.25) 0.42 (0.29) 0.30 (0.21) 0.000†
GP4 15.68 (6.15) 16.74 (5.28) 14.57 (6.07) 0.000†
GP5 0.23 (0.09) 0.26 (0.08) 0.22 (0.08) 0.000†
GP6 3.82 (1.59) 4.37 (1.44) 3.53 (1.31) 0.000†
GP7 0.58 (0.34) 0.63 (0.41) 0.56 (0.31) 0.005†
GP8 18.58 (2.25) 18.69 (2.40) 18.53 (2.27) 0.054‡
GP9 9.67 (1.73) 9.84 (1.83) 9.58 (1.76) 0.065‡
GP10 5.04 (1.24) 5.22 (1.55) 4.89 (1.13) 0.000†
GP11 0.68 (0.17) 0.71 (0.20) 0.66 (0.16) 0.000†
GP12 0.96 (0.61) 0.89 (0.59) 1.00 (0.63) 0.037†
GP13 0.46 (0.16) 0.45 (0.16) 0.47 (0.15) 0.049
GP14 17.95 (5.1) 16.55 (3.59) 18.91 (5.01) 0.000†,‡
GP15 1.96 (0.58) 1.90 (0.57) 1.99 (0.58) 0.017†
GP16 3.07 (0.69) 3.09 (0.73) 3.06 (0.69) 0.223‡
GP17 0.99 (0.32) 0.98 (0.34) 1.00 (0.32) 0.110
GP18 12.06 (4.04) 11.04 (3.01) 12.72 (4.25) 0.000†
GP19 1.88 (0.44) 1.92 (0.49) 1.86 (0.42) 0.005†
GP21 0.68 (0.21) 0.69 (0.23) 0.67 (0.20) 0.167
GP22 0.10 (0.05) 0.1 (0.05) 0.1 (0.05) 0.172
GP23 1.65 (0.80) 1.55 (0.83) 1.69 (0.78) 0.079
GP24 1.60 (0.59) 1.66 (0.61) 1.56 (0.60) 0.043†
GP = glycan peak, IgG = immunoglobulin G.
∗
Data are presented as median (interquartile range).
† P<0.05; difference between male and female is statistically significant.
‡ Those variables are normally distributed and the difference between male and female was tested
using 2-sample t test. GP values were presented as percentages of the total IgG glycome. GP1 to 24
represent GP values 1 to 24.
Table 3
Associations of immunoglobulin G glycans with age.
GP
Pooled Male Female
R P value R P value R P value
GP1 0.248 0.000 0.108 0.092 0.306 0.000
GP2 0.340 0.000 0.147 0.022 0.415 0.000
GP4 0.419 0.000 0.264 0.000 0.477 0.000
GP5 0.223 0.000 0.075 0.241 0.279 0.000
GP6 0.516 0.000 0.368 0.000 0.576 0.000
GP7 0.095 0.012 0.007 0.916 0.123 0.008
GP8 0.091 0.016 0.135 0.035 0.223 0.000
GP9 0.108 0.004 0.009 0.884 0.163 0.000
GP10 0.318 0.000 0.263 0.000 0.335 0.000
GP11 0.327 0.000 0.302 0.000 0.313 0.000
GP12 0.235 0.000 0.109 0.089 0.305 0.000
GP13 0.195 0.000 0.178 0.005 0.203 0.000
GP14 0.504 0.000 0.367 0.000 0.536 0.000
GP15 0.173 0.000 0.041 0.522 0.288 0.000
GP16 0.062 0.104 0.099 0.124 0.024 0.609
GP17 0.180 0.000 0.056 0.383 0.254 0.000
GP18 0.443 0.000 0.250 0.000 0.512 0.000
GP19 0.074 0.049 0.213 0.001 0.035 0.455
GP21 0.081 0.031 0.065 0.314 0.107 0.022
GP22 0.027 0.481 0.055 0.393 0.023 0.631
GP23 0.202 0.000 0.156 0.015 0.220 0.000
GP24 0.062 0.099 0.104 0.106 0.018 0.697
GP1 to 24 represent GP values 1 to 24. GP = glycan peak, R = Spearman correlation coefficient.
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terminal sialic acid (FA2G2S1, FA2G2S2) significantly decreased
with age in both males and females.
3.4. Predictive model of chronological age from IgG
N-glycans
As different groups of glycans were related with chronological
age in pooled, male, and female samples, 10 age-related GPs were
used for the construction of GlyAge-Pooled model, 11 GPs for
GlyAge-Male model, and 18 GPs for GlyAge-Female model. The
GlyAge indexes in pooled, male, and female samples composed of
the following different glycan variables:
GlyAge-Pooled model:
Predicted age ¼ 73:5 ð1:1  GP82Þ þ ð2:1  GP102Þ
ð2:2  GP142Þ  ð0:7  GP182Þ
GlyAge-Male model:
Predicted male age ¼ 54:5þ ð39:5  GP6Þ  ð14:2
GP62Þ  ð2:5  GP82Þ þ ð3:2  GP102Þ
þð2:5  GP132Þ  ð2:8  GP142Þ
GlyAge-Female model:
Predicted female age ¼ 1:9þ ð6:1  GP7Þ þ ð10:7
GP9Þ þ ð11:8  GP10Þ  ð9:2  GP11Þ  ð7:94
 GP12Þ þ ð5:6  GP17Þ þ ð2:8  GP62Þ þ ð1:9
 GP232Þ
The GlyAge-Pooled model contains 2 monogalactosylated
glycans (FA2[6]G1 and FA2[6]BG1), 1 digalactosylated
glycan (FA2G2), and 1 digalactosylated monosialylated glycan
(GA2G2S1), thus covering nearly all elements of IgG glycosyla-
tion. This GlyAge-Pooled model explained 29.4% of variation in
chronological age in pooled samples and the correlation of age
and predicted age was 0.56 (P<0.001). The predictions based on
male and female samples were fluctuating, with correlation
between age and predicted age of 0.45 and 0.60 (P<0.001)
(Table 5).
In terms of GlyAge-Male model, the proportion of explained
variation was 23.2% and the correlation of age and predicted
age was 0.50 in male samples. The correlations increased to
0.55 and 0.57 (P<0.001) when the GlyAge-Male model was
applied in the pooled and female samples, respectively (Table 5).
The nongalactosylated, monogalactosylated, and digalactosy-
lated glycans (FA2B, FA2[6]BG1, A2BG2, FA2G2) were all
involved in this model, but the impact of sialylation was not
included.
For the GlyAge-Female model, up to 45.4% variations in
chronological age could be explained in female samples, with
the correlation between age and predicted age of 0.65 (P<
0.001). However, the correlation coefficient dropped to 0.58
and 0.40 (P<0.001) when GlyAge-Female model was tested in
pooled and male samples, respectively (Table 5). This indicated
that the associations between age and glycans vary in sexes and
the glycans showed stronger correlations with age in females
than in males.
3.5. Relationship between IgG glycosylation and biological
age
To determine variables that may be responsible for the remaining
variability in the GlyAge-Pooled, GlyAge-Male, and GlyAge-
Female indexes, we performed an association analysis among all
clinical traits. The traits (10 traits in pooled samples, 6 traits in
males, and 5 traits in females) such as DBP, FPG, ALT, AST,
WBC, and UA with statistically significant association with
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Figure 1. The line graph of relationship between age and selected glycan structures. Plots describe associations between the individual contributions of 12
selected glycan structures to the total IgG glycome and chronological age. Blue and red curves are fitted linear regression models. The shaded region is the 95%
confidence interval on the fitted values. GP = glycan peak, IgG = immunoglobulin G.
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GlyAge indexes were also well known to be significantly related
with unhealthy lifestyles or inflammation process (Table 4; see
Table 5, Supplemental Content, http://links.lww.com/MD/B95,
which illustrates association of GlyAge index with clinical traits
after adjustment of chronological age).
Many clinical traits were significantly associated with both the
predicted age (predicted by GlyAge-Pooled, GlyAge-Male, and
GlyAge-Female models) and the chronological age (see Table 6,
Supplemental Content, http://links.lww.com/MD/B95, which
illustrates association of chronological and GlyAge with clinical
traits in pool, male, and female samples). Hence, we attempted to
take the information fromboth clinical traits and glycan structures
to build a combined, comprehensive age predictive model.
3.6. Combined predictive model of chronological age from
IgG N-glycans and clinical traits
In pooled samples, inclusion of SBP, LDL, hemoglobin, MCV,
urea, and UA into GlyAge-Pooled model further improved the
prediction power and cumulatively explained 36.1%variation of
age in pooled samples and the correlation between age and
predicted age was increased to 0.59 (P<0.001). This combined
model was named as GlyCliAge-Pooled model. When the
GlyCliAge-Pooled model was tested in male and female samples,
the correlations between age and predicted age were 0.51 and
0.61 (P<0.001), respectively. Similarly in male samples, the
proportion of explained variance of age increased to 36.7%with
correlation between age and predicted male age of 0.47 when
FPG, ALT, urea, and MCV were included into GlyAge-Male
model. This GlyCliAge-Male model was also applied in other
2 groups of samples, pooled and male samples, and the
associations between age and predicted age were nearly the
same (0.45 and 0.41). In females, inclusion of clinical traits (SBP,
TC,HDL, andCr) could improve the predictive ability of glyAge-
Female model to 48.2% but the correlation between age and
predicted age decreased to 0.29 in males, and 0.46 in pooled
samples (Table 5). The combined models based on the pooled,
male, and female samples are as follows:
GlyCliAge-Pooled model:
Predicted age ¼ 43:39þ ð1:98  GP102Þ
ð2:47  GP142Þ þ ð0:06  SBPÞ þ ð1:34
LDLÞ þ ð0:67  ureaÞð0:00007  Hb2Þ
þð0:0009  MCV2Þ  ð0:00002  UA2Þ
Table 5
Adjusted R-squared and Spearman correlations of chronological age and age predicted by various models.
Model
Pooled Male Female
R2, % Correlation R2, % Correlation R2, % Correlation
GlyAge 29.4 0.56 — 0.45 — 0.60
GlyAge-Male — 0.55 23.2 0.50 — 0.57
GlyAge-Female — 0.58 — 0.40 45.4 0.65
GlyCliAge 36.1 0.59 — 0.51 — 0.61
GlyCliAge-Male — 0.45 36.7 0.47 — 0.41
GlyCliAge-Female — 0.46 — 0.29 48.2 0.67
GlyAge-Euro-male
∗
— 0.54 — 0.41 — 0.57
GlyAge-Euro-female† — 0.40 — 0.30 — 0.43
∗
The age predictive model for males built based on European population.
† The age predictive model for females built based on European population.
Table 4
Association of GlyAge indexes with clinical traits after adjustment of chronological age.
Traits
GlyAge-Pool index GlyAge-Male index GlyAge-Female index
Regression coefficient
∗
P Regression coefficient† P Regression coefficient‡ P
SBP 0.0072 0.375 0.0349 0.030 0.0077 0.442
DBP 0.0220 0.051 0.0626 0.005 0.0018 0.894
WC 0.0323 0.022 0.0095 0.727 0.0078 0.654
Heart rate 0.0242 0.038 0.0194 0.407 0.0235 0.099
FPG 0.3687 0.010 0.4863 0.042 0.4854 0.016
TC 0.3619 0.003 0.2480 0.298 0.2934 0.061
TG 0.2375 0.004 0.1811 0.203 0.2085 0.061
LDL 0.3381 0.030 0.0816 0.783 0.3513 0.081
HDL 0.2020 0.538 1.7450 0.018 0.1241 0.744
ALT 0.0195 0.002 0.0093 0.294 0.0326 0.004
AST 0.0540 0.000 0.0500 0.041 0.0502 0.003
Cr 0.0167 0.224 0.0287 0.199 0.0111 0.577
WBC 0.1383 0.044 0.3500 0.003 0.0688 0.453
Urea 0.1501 0.111 0.0793 0.651 0.3572 0.003
UA 0.0088 0.000 0.0064 0.059 0.0095 0.000
ALT = alanine aminotransferase, AST = aspartate aminotransferase, Cr = creatinine, DBP = diastolic blood pressure, FPG = fasting plasma glucose, HDL = high-density lipoprotein, LDL = low-density
lipoprotein, SBP = systolic blood pressure, TC = total cholesterol, TG = triglyceride, UA = uric acid, WBC = white blood cell count, WC = waist circumference.
∗
The regression coefficient was calculated in pooled samples.
† The regression coefficient was calculated in male samples.
‡ The regression coefficient was calculated in female samples.
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GlyCliAge-Male model:
Predicted male age ¼ 0:87þ ð1:68  GP102Þ  ð2:45
GP142Þ þ ð11:66  FPGÞ  ð0:13  ALTÞ
þ ð0:96  ureaÞð0:76  FPG2Þ
þ ð0:0003  ALT2Þ þ ð0:002  MCV2Þ
GlyCliAge-Female model:
Predicted female age ¼ 26:41þ ð5:89  GP7Þ  ð6:08
GP12Þ þ ð2:33  GP62Þ  ð0:04
 SBPÞ  ð1:13  TCÞ þ ð8:62
 HDLÞ  ð2:24  HDL2Þ
þ ð0:0007  Cr2Þ
4. Discussion
Many epidemiological studies and experimental observations
have demonstrated that changes in IgG Fc glycosylation induce
pro-inflammatory or anti-inflammatory actions of Igs,[10,20,39,40]
indicating that IgG Fc glycosylation plays an important role in the
process of aging.[29,41] The reduction of terminal galactose
residues was suggested as a mechanism to enhance the pro-
inflammatory activity in vitro.[42] Our study was consistent with
that hypothesis by observing a lower level of galactosylation in
males who had a higher WBC, a classic clinical inflammatory
index, than that in females. Furthermore, higher sialylation was
found in males, which seemed contradictory with findings of
previous studies because those results showed the anti-inflam-
matory properties of binding sialic acid residue to IgG Fc
fragment.[43] However, the observations in our study may still be
understood in the following context. First, the anti-inflammatory
properties did not only depend on the amount of sialic acid but
also required attachment of the oligosaccharides in an a2, 6
linkage.[44] The mix of 2 different linkage structures (a2, 6 and
a2, 3) in this study may weaken the anti-inflammatory activity.
Second, although the WBC in males was higher than that in
females, both of the values were still in the normal range and all
the participants were recruited from the same community with
general homogenous environment background. Thus, more
heavily sialylated glycan structures might be needed to balance
the pro-inflammatory properties caused by the lower galactosy-
lation in males (Tables 1 and 2). Those results indicated that these
glycan structures are associated with an inflammatory condition,
which is a significant risk factor in the aging process.
A combined genomics and epigenomics study indicated that
the structure of glycan moiety is defined by dynamic interactions
between their encoding genes, their protein products, and
environmental factors.[45] For the total plasma N-glycans, only
5% of the variance in glycans can be explained by nongenetic
variables, such as age, BMI, and plasma lipid profiles.[33] The
average heritability of 24 IgG N-glycan traits in TwinsUK study
was 0.49, indicating that the nongenetic factors contributed a
little bit more than half of the variance to the levels of those N-
glycan traits.[35] As we can see in our study, a large part of the
nongenetic variability in IgG N-glycan structures was able to be
explained by age and clinical traits related to age. Most of IgG
glycans (19 out of 22 GPs) were significantly related with age in
which the prominent trend we observed is the decrease in IgG
galactosylation with age (Table 3). Studies in European
population showed a similar glycan profiling change more than
15 years ago, but 1 recent investigation indicated that the
galactosylation is increasing with age in children from 6 to 18
years old.[46] Because the participants in our study were in the age
of 23 to 68, it was possible that the level of galactosylation would
increase until adolescence (about 18 years old) and then decrease
during the maturing life span. In addition, the association
patterns between IgGN-glycan traits and age were more complex
in community-based study due to the diversity of the patterns in
sexes (Fig. 1; see Fig. Supplemental Content, http://links.lww.
com/MD/B95, which illustrates the relationship between age and
glycan structures). High level of galactosylation in IgGN-glycans
played a critical role in anti-inflammatory process[47] and in this
way contributed to protect people from aging and age-related
diseases,[48] such as inflammaging,[41,49] but the physiopatholog-
ical mechanisms were still controversial.[40]
Besides the level of galactosylation, the sialylation levels were
also suggested to be an essential role in the anti-inflammatory
activities of IgG antibodies[44,50] and therefore might be involved
in the aging process. Disialylated biantennary glycans were
reported to increase with age in children, whereas monosialylated
biantennary glycans showed no statistical significant associa-
tion.[46] For the adults in our study, however, both monosialy-
lated and bisialylated biantennary glycans were decreased with
age in both males and females. Like the galactosylation, the
change of sialylation level wasmore dramatic in females than that
in males. Those phenomena indicated the different changing
patterns between children and adults, and also between males
and females.
To our knowledge, this is the first attempt to build a predictive
model of chronological age using the information from both IgG
glycans and clinical parameters in a Han Chinese population.
Here, we first built 3 models (GlyAge-Pooled, GlyAge-Male, and
GlyAge-Female models) and introduced 3 Glycan indexes
(GlyAge-Pooled index, GlyAge-Male index, and GlyAge-Female
index) accordingly to predict chronological age using informa-
tion only from IgG glycans based on pooled, male, and female
samples, respectively. These indexes could explain 23.2% to
45.4% of variation in chronological age with the relationship
between age and predicted age of 0.40 to 0.65 in the investigated
samples. Compared to the reported single age biomarkers, such
as telomere length which based on the literature data can explain
15% to 25% of variance in chronological age, the GlyAge
indexes in our study that integrated the information from IgG N-
glycans were shown to be more closely related to chronological
age.
After adjustment of chronological age, a strong correlation
between the 3 GlyAge indexes and the clinical traits that related
to biological ages was also observed (Table 4). Thus, IgG
glycosylation appeared to be associated with both chronological
and biological ages. Consistent with this, inclusion of clinical
traits into the previous prediction models could improve the
prediction especially for the GlyAge-Pooledmodel. By integrating
the clinical traits, the proportion of explained variation in age
increased from 29.4% to 36.1%. For the GlyCliAge-Female
model as well, nearly half (48.2%) of the variation of age could be
explained by the glycans and clinical traits (Table 5).
To test these 6 models and to determine a general model, we
applied them to the pooled, male, and female samples separately.
According to the association between predicted age and
chronological age, the predictive ability of GlyCliAge-Pooled
model was acceptable with correlation coefficient of 0.59 in
pooled samples, 0.51 in males, and 0.61 in females, which is
higher than those in the rest of models. This indicated that
although both glycans and clinical traits were different between
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sexes, the combined index could still be applied in all the
investigated participants, which would benefit its practicability in
community-based population study.
In addition to the 6models we built, we also tried to validate, in
this study population, 2 established sex-specific models for age
prediction, which were built based on European population
study.[30] The correlation coefficient between the predicted and
the chronological age was 0.41 (0.43) when we applied the model
for males (females) in our Chinese study population. Both of these
correlation coefficients were lower than those in the models built
in our study. In addition to the sex difference, those observations
suggested that the ethnic difference should also be considered
when applying these age predictive models.
Models that can indicate biological age are of significant
interest for prevention, diagnosis, and monitoring (and/or
the treatment) of aging and age-related diseases. Changes of
the inflammatory states have been proved to be involved in the
aging process and IgG glycosylation plays an essential role in the
inflammatory cascade.[1,20,41] Therefore, the inclusion of IgG
glycan information becomes the most interesting consideration in
building an age predictive model. The limitation of this study is
that models we introduced are built based only on the data we
collected, so studies with larger sample size and different ethnic
groups are needed to validate and improve the models. Also,
the current correlation between N-glycans and aging needs to be
further validated before its clinical application.
5. Conclusions
Our study showed that most of IgG glycans were significantly
related with chronological age inHanChinese population andwe
illustrated extensive patterns of the changes in IgG glycans with
age. The age predictive models consisted of 12 glycan structures
(4 for GlyAge-Pooled model, 6 for GlyAge-Male model, and
8 for GlyAge-Female model) and explained 23.2% to 45.4% of
variance in age. The remaining variance in these glycans was
associated with clinical traits related to biological age. Therefore,
IgG glycosylation seems to correlate with both chronological and
biological ages and thus contribute to aging process. It was
further supported by including the clinical traits such as SBP,
LDL, and urea in the prediction models, which significantly
increased the prediction and cumulatively explained 48.2% of
variation in chronological age in females. Models that can
indicate biological age are of significant interest for prevention,
diagnosis, and monitoring (and/or the treatment) of aging and
age-related diseases.
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